<DOC>
	<DOCNO>NCT01934933</DOCNO>
	<brief_summary>This prospective , open-label trial evaluate efficacy delay ossification improve inflammation celebrex treatment active ankylosing spondylitis ( AS ) . Subjects randomly divide three group ( Enbrel group , Celebrex group Enbrel plus Celebrex group ) receive responsable treatment 54 week . Clinical response assessment , laboratory assessment radiology assessment record . Primary endpoint magnetic resonance imaging ( MRI ) Spondyloarthritis Research Consortium Canada ( SPARCC ) score modify Stoke Ankylosing Spondylitis Spinal Score ( mSASSS ) spine sacroiliac ( SI ) joint , well Assessment SpondyloArthritis International Society ( ASAS ) 20 response rate . Secondary Endpoints include ASAS20 , ASAS40 , ASAS70 ASAS5/6 response rate visit clinical index .</brief_summary>
	<brief_title>Delaying Ossification Improving Inflammation Celebrex Plus/or Enbrel Treatment Active Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>18 65 year Meet 1984 NewYork modify criterion AS BASDAI≥4 ASDAS score ≥ 2.1 CRP＞6 mg/L ESR＞28 mm/h Syndesmophyte quantity ≥2 ＜16 spine Sexually active woman childbearing potential must agree commit use medically accept form contraception No active latent tuberculosis infection . Pregnant breastfeed woman current previous history psoriasis inflammatory bowel disease . infection clinical significance within 24 week screen receipt bioagents treatment within 12 week screen corticosteroid intraarticular injection last 3 month trial Significant concurrent medical event include : Gastrointestinal ulcer , myocardial infarction within 12 month screen visit , unstable angina pectoris , congestive heart failure . Alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>ossification</keyword>
	<keyword>etanercept</keyword>
</DOC>